shutterstock_1635596416_sundry_photography
Sundry Photography / Shutterstock.com
16 November 2021Big PharmaAlex Baldwin

Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

Amgen and two research centres have thrown their support behind Bristol Myers Squibb subsidiary Juno Therapeutics to help restore a $1.1 billion patent judgment against Kite Pharma that was overturned by the US Court of Appeals for the Federal Circuit.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
15 December 2022   As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.
Americas
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
8 August 2022   Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

More on this story

Americas
15 December 2022   As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.
Americas
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
8 August 2022   Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

More on this story

Americas
15 December 2022   As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.
Americas
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
8 August 2022   Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.